• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a pharmaceutical or veterinary composition for its use in the prevention and / or treatment of an infection with the coronavirus MERS-CoV (Middle East Respiratory Syndrome Coronavirus), characterized in that it comprises, in a vehicle pharmaceutical composition, at least one compound selected from apigenin and berberine.
    公开号:FR3057773A1
    申请号:FR1660223
    申请日:2016-10-21
    公开日:2018-04-27
    发明作者:Manuel Rosa-Calatrava；Olivier Terrier；Anais Proust；Vincent Moules
    申请人:Centre National de la Recherche Scientifique CNRS；Universite Claude Bernard Lyon 1 UCBL；Institut National de la Sante et de la Recherche Medicale INSERM；
    IPC主号:
    专利说明:

    Holder (s): CLAUDE BERNARD LYON UNIVERSITY 1 Public establishment, INSERM (NATIONAL INSTITUTE OF HEALTH AND MEDICAL RESEARCH), NATIONAL CENTER OF SCIENTIFIC RESEARCH Public establishment.
    Extension request (s)
    Agent (s): REGIMBEAU.
    NOVEL ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS-RELATED INFECTIONS.
    The present invention relates to a pharmaceutical or veterinary composition for its use in the prevention and / or treatment of an infection by the coronavirus MERS-CoV (Middle-East Respiratory Syndrome Coronavirus), characterized in that it comprises, in a vehicle suitable pharmaceutical, at least one compound chosen from apigenin and berberine.
    FR 3 057 773 - A1
    i
    NOVEL ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF
    CORONAVIRUS-RELATED INFECTIONS
    The present invention relates to compositions for their use in the treatment of viral infections linked to the MERS-CoV coronavirus (Middle East Respiratory Syndrome), in humans and in animals.
    The MERS-CoV coronavirus is a new emerging virus identified in 2012 in Saudi Arabia, responsible for severe acute respiratory syndrome and kidney failure. Since its identification, this virus has been responsible for more than 1,806 cases of infection in 26 countries, mainly in the Middle East. It is responsible for 643 deaths, or almost 35.6% of mortality according to the World Health Organization (Source WHO, September 28, 2016).
    MERS-CoV belongs to the order of Nidovirals, to the family of Coronaviridae, and to the genus Betacoronavirus.
    Coronaviruses are enveloped viruses, having a capsid having a helical symmetry. They have a positive-sense single-stranded RNA genome and are able to infect cells in birds and mammals. The viruses belonging to this very large family are known to be causative agents of colds (for example the hCoV and OC43 viruses), bronchiolitis (for example the NL63 virus) or even certain forms of severe pneumonia such as those observed during SARS epidemic (such as the Severe Acute Respiratory Syndrome Coronavirus, SARS-CoV).
    Despite their belonging to the same viral family, important differences exist between the different coronaviruses, both at the genetic and structural level, but also in terms of biology and sensitivity to antiviral molecules, (see for reference Dijkman & van der Hoek 2009; de Wit et al., 2016)
    Although the majority of cases of MERS-CoV in humans are attributable to human-to-human transmission, the camel appears to be a permanent intermediate infected animal host of MERS-CoV and thus constitutes the main animal source of infection in humans. .
    There is currently no prophylactic or therapeutic solution to effectively treat this epidemic respiratory viral pathogen with pandemic potential.
    Several therapeutic avenues have recently been explored: use of ribavirin, interferon, or mycophenolic acid. Unfortunately, most of these compounds have not shown sufficient efficacy, when used in infected patients (Al-Tawfiq et al., 2014) or as part of prophylactic treatment (de Wit et al., 2016 .).
    A first strategy for the identification of active compounds against MERS-CoV was to test, among the many known antiviral molecules, those used to fight SARS-CoV. Thus, inhibitors of viral replication, such as protease inhibitors, helicase inhibitors, and inhibitors of entry of the virus into the target cells were tested in vitro (see for review Adedeji & Sarafianos, 2014, and Kilianski & Baker, 2014).
    Dyall et al. (Dyall et al., 2014) tested different categories of drugs in order to identify antiviral agents active on the SARS and / or MERS-VOC coronaviruses. Among the different classes of agents tested, it was shown that certain anti-inflammatory agents inhibited the proliferation of SARS-CoV, while MERS-CoV was rather inhibited by certain inhibitors of ion transport, inhibitors of tubulin, or apoptosis inhibitors. Out of 290 compounds tested, only 33 compounds exhibiting antiviral activity on MERS-CoV were identified in cell culture.
    However, numerous data in the literature indicate that the antiviral compounds effective on SARS-CoV are not systematically active against MERSCoV, and vice versa; these viruses having differences in terms of both protein composition and functional interactions with the host cell. (Dijkman & van der Hoek 2009; Dyall et al., 2014)
    An alternative strategy to identify new therapeutic molecules is to test molecules having an action on the signaling, biogenesis and cellular metabolic pathways that target and / or divert for their benefit viruses to carry out their replicative cycle. This strategy, presented in the article by Josset et al. (Plos One, 2010), has already enabled the identification of molecules exhibiting antiviral activity against influenza viruses, such as the molecules presented in patent applications FR 2 953 410, FR1552284 and FR1653057.
    Furthermore, Josset et al. Have highlighted the fact that MERSCoV induces a gene expression profile of the target cells it infects, quite different from that induced by SARS-CoV. According to this study, glucocorticoid and kinase inhibitors could be the preferred pharmaceutical classes for the search for active antiviral compounds on the MERS-VOC coronavirus. (Josset et al., 2013).
    Currently, there are no, or very few, therapeutic molecules recognized and / or approved by health authorities to fight infections with the MERS-CoV virus.
    Furthermore, there is no vaccine on the market against the MERS-CoV virus. Some candidates are currently being evaluated in a Phase I clinical trial (Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers - Full Text View ClinicalTrials.gov, ”accessed March 24, 2016, https://clinicaltrials.gov / ct2 / show / NCT02670187 term = MERS + coronavirus & rank = 7).
    Under these conditions, there is a need for new prophylactic and / or therapeutic solutions against infections by the MERSCOV coronavirus.
    SUMMARY OF THE INVENTION
    In the context of the present invention, several compounds have been selected and evaluated in a cell test for viral infection. Certain compounds have thus exhibited an unexpected antiviral effect on the MERS-CoV coronavirus.
    The selected compounds had been previously described for other therapeutic applications. Surprisingly, it has now been shown that these compounds, alone or in combination, have antiviral activity against MERS-CoV, and allow the treatment and / or prevention of infections by this coronavirus.
    The invention relates to pharmaceutical or veterinary compositions for their use in the prevention and / or treatment of a MERS-COV (Middle-East Respiratory Syndrome) coronavirus infection, characterized in that they comprise, in a pharmaceutical vehicle suitable, at least one compound chosen from Apigenin and Berberine.
    The invention also relates to a pharmaceutical or veterinary composition for its use in the prevention and / or treatment of an infection with the coronavirus MERS-COV (Middle-East Respiratory Syndrome), characterized in that it comprises, in an appropriate pharmaceutical vehicle, at least one compound chosen from apigenin, berberine and monensin, or a combination of at least two of these compounds.
    These pharmaceutical or veterinary compositions can advantageously further comprise at least one other antiviral agent, and / or an antibacterial agent. Within the meaning of the invention, another antiviral agent is an agent distinct from apigenin, berberine and monensin. Also, within the meaning of the invention, an antibacterial agent is an agent distinct from apigenin, berberine and monensin.
    A subject of the invention is also pharmaceutical or veterinary compositions comprising at least one antiviral agent in combination with at least one compound chosen from apigenin, berberine and monensin, or a combination of two of these compounds, or a combination of these three compounds.
    In particular, said composition comprises, in an appropriate pharmaceutical vehicle, at least two compounds chosen from:
    (a) an antiviral agent; and (b) a compound selected from apigenin, berberine, and a combination of the two.
    The subject of the invention is also pharmaceutical or veterinary compositions, comprising in a suitable pharmaceutical vehicle, a combination of berberine and monensine.
    According to a particular aspect of the invention, said compositions are in a galenical form intended for administration by inhalation
    FIGURES
    Figure 1. Measurement of the infectious titers of MERS-CoV at 24 hours post-infection, on cells treated (with monensin, berberine or apigenin), reported as the infectious titre of infected and untreated control cells. The infectious titers were obtained by infection technique by limiting dilution and calculation by the method of Reed and Muench.
    A) The results are expressed in log10 TCID / mL (50% Tissue Culture Infective Dose)
    B) The results are expressed in TCID / mL
    Figure 2. Measurement of IC50 (concentration necessary to obtain 50% of normalized viral production) of the compounds tested (A-monensin, B-berberine, C-apigenin) on VeroE6 cells infected with the coronavirus MERS-VOC. The infectious titers were obtained by infection technique by limiting dilution and calculation by the method of Reed and Muench.
    Figure 3. Measuring the antiviral efficacy of the tested compounds (A-monensin, B-apigenin, C-berberine) on human respiratory epithelial cells A549 infected with the MERS-VOC coronavirus: The infectious titers were obtained by infection technique by limiting dilution and calculation by the Reed and Muench method. The normalized viral production is measured in parallel with the viability of the cells, as a function of the concentration of compounds used.
    DETAILED DESCRIPTION OF THE INVENTION
    The present invention relates to a pharmaceutical or veterinary composition for its use in the prevention and / or treatment of an infection with the coronavirus MERS-CoV (Middle-East Respiratory Syndrome), characterized in that it comprises, in a pharmaceutical vehicle suitable, at least one compound chosen from Apigenin and Berberine.
    The compositions according to the invention are in particular intended for use in the treatment of an infection with the MERS-VOC coronavirus.
    By “infection with the MERS-CoV coronavirus” is meant the fact that an organism, human or animal, has cells which have been infected with the MERS-CoV coronavirus. The infection can in particular be established by carrying out detection and / or viral titration from respiratory samples, or by assaying the specific antibodies of MERS-CoV circulating in the blood. Detection in infected individuals of this specific virus is carried out by conventional diagnostic methods, in particular molecular biology (PCR), well known to those skilled in the art.
    The term "treatment" refers to fighting infection with the MERS-CoV coronavirus in a human or animal body. Thanks to the administration of at least one composition according to the invention, the rate of viral infection (infectious titer) in the organism will decrease, and preferably the virus will disappear completely from the organism. The term "treatment" also refers to alleviating the symptoms associated with viral infection (respiratory syndrome, kidney failure, fever, etc.).
    The compositions according to the invention are also intended for use in the prevention of infection with MERS-CoV.
    Within the meaning of the invention, the term “prevention” designates the fact of preventing, or at least reducing the probability of occurrence, of an infection in a human or animal organism with MERS-CoV. Thanks to the administration of at least one composition according to the invention, the human or animal cells of said organism become less permissive to infection, and are thus more likely not to be infected with said coronavirus.
    The compositions according to the invention may be of the pharmaceutical type, intended to be administered to a human being, or of the veterinary type, intended to be administered to non-human animals.
    With regard to animals, it is understood that the veterinary compositions for their use in the prevention and / or treatment of an infection by the coronavirus MERS-CoV (Middle-East Respiratory Syndrome) are intended to be administered to animals infected with this coronavirus. These compositions are in particular intended for mammals, in particular for production animals, and in particular for mammals of the camelid family and very particularly for the camel (genus Camelus). According to the invention, the term “suitable pharmaceutical vehicle” designates vehicles or excipients, that is to say compounds which do not have a specific action on the infection considered here. These vehicles or excipients are pharmaceutically acceptable, which means that they can be administered to an individual or an animal without generating significant deleterious effects.
    According to a first aspect, the pharmaceutical or veterinary composition for its use according to the invention comprises at least one effective amount of apigenin.
    According to a second aspect, the pharmaceutical or veterinary composition for its use according to the invention comprises at least an effective amount of berberine.
    By "effective amount" is meant in the sense of the invention an amount of active compound sufficient to inhibit the proliferation and / or replication of the coronavirus, and / or the development of viral infection within the organism. This inhibition can be quantified, for example by measuring the viral titer as presented in the examples of the present application.
    According to a preferred aspect of the invention, said pharmaceutical or veterinary composition for its use as cited above is characterized in that it comprises a combination of at least two of the following compounds: apigenin, berberine and monensin.
    Said pharmaceutical composition may in particular comprise one of the following combinations:
    - Apigenin and Berberine;
    - Apigenin and Monensine;
    - Berberine and Monensine; or
    - Apigenin, Berberine and Monensine.
    According to a particular aspect of the invention, the pharmaceutical composition for its use according to the invention will consist of one of the combinations of compounds as mentioned above, and a suitable pharmaceutical vehicle.
    These compounds are known for use in other therapeutic applications not directly related to antiviral activity against the MERSCoV coronavirus, as presented below.
    Apigenin
    Apigenin is a natural compound in the flavone family (flavonoids), found in parsley, plantain, yarrow, passionflower and rosemary.
    Its developed chemical structure is shown below:
    This molecule is known for its anti-inflammatory properties, although its mode of action is not known in detail. Some studies indicate that apigenin works by inhibiting cytochrome P450.
    Apigenin has shown its effectiveness against certain viruses, such as the HCV virus of hepatitis C (Shibata et al. 2014), enterovirus 71 (Lv et al. 2014) or the gamma virus of herpes (WO 2016/013793).
    Berberine
    Berberine is a natural alkaloid found in many plants.
    Its developed chemical structure is shown below:
    Formula II
    This molecule is widely used in the Asian pharmacopoeia, for its antifungal, antibacterial and anti-inflammatory properties.
    Its mechanism of action, although not fully understood, is mainly due to the activation of AMP Kinase (Adenosine Monophosphate activated Protein Kinase). This ubiquitous enzyme plays a role in cellular energy homeostasis. The activation of ΓΑΜΡΚ mainly has the effect of (i) stimulating the oxidation of hepatic fatty acids and ketogenesis, (ii) inhibiting the synthesis of cholesterol, lipogenesis and the synthesis of triglycerides, (iii) stimulating the oxidation of fatty acids in skeletal muscles and absorption of glucose by muscles and (iv) modulate insulin secretion by beta cells in the pancreas.
    Berberine has antiviral activity on the HSV virus (Song et al. 2014) and on influenza viruses (Wu et al. 2011).
    In addition, berberine may exhibit antiviral action against SARSCoV (http://apps.who.int/medicinedocs/fi7d/Js6170e/ and WO 2013/185126), although no experimental data are available.
    Monensin
    Monensin is a polyether antibiotic isolated from a bacteria of the genus Streptomyces. This molecule is very widely used as an additive in the feed of ruminants (under the trade name Rumensin®), to prevent coccidiosis-like infections.
    Its developed chemical structure is shown below:
    OH
    Formula III
    Monensin acts as an ionophore, disrupting intracellular traffic.
    This molecule is known to exhibit significant cytotoxicity when used at high concentrations. In animals, very significant differences in LD50 (Lethal Dose 50%) exist. For example, in horses, the LD50 is 100 times lower than in ruminants, which poses very serious problems of intoxication by cross-contamination of food on some farms.
    An increasing number of data in the literature also shows an anti-malarial activity, as well as an antiviral activity against several viruses: against influenza viruses (FR1552284 and FR1653057) and more particularly against enveloped viruses, including certain family member viruses. coronaviruses.
    The application US 2009/0149545 cites numerous compounds, and in particular monensin, for its therapeutic action against infection by coronavirus.
    Patent application WO 2015/157223, relating to the search for compounds having antiviral activity against coronaviruses, reports that monensin could be êtreο used against MERS-CoV, without however presenting experimental results making it possible to establish this conclusion.
    Antiviral agent
    Within the meaning of the present invention, the terms “antiviral agent” or “antiviral compound” are understood to mean active agents which act on the viral load (also called infectious titre), by inhibiting either directly or indirectly replication and / or the dissemination of the MERS-CoV coronavirus within an infected organism.
    By “antiviral activity” or “antiviral action” is meant an action on the virus or on its target cells, in particular the action of inhibiting the replication cycle of the virus or its capacity to infect and reproduce in host cells. , this antiviral effect being obtainable by the modulation of a certain number of genes of the target cells.
    "Target cells" means cells infected with the coronavirus and / or likely to be infected soon, by their immediate proximity to infected cells.
    Combination with another active agent
    It is understood that the composition for its use according to the invention comprises apigenin and / or berberine, and that it can therefore also comprise other active compounds, in addition to the appropriate pharmaceutical vehicle.
    Indeed, apigenin, berberine and monensin, or their mixtures, can be used in therapy alone, or in combination with at least one other active agent.
    They may be compounds making it possible to improve the activity of these compounds, or else other active agents known for a particular activity.
    These additional active compounds may be chosen from the pharmaceutical classes of agents cited in application WO 2015/157223, namely from antibacterial agents, antiparasitic agents, neurotransmission inhibitors, estrogen receptor inhibitors, inhibitors of DNA synthesis and replication, protein maturation inhibitors, kinase pathway inhibitors, cytoskeleton inhibitors, lipid metabolism inhibitors, anti3057773 inflammatory agents, ion channel inhibitors, apoptosis inhibitors and cathepsin inhibitors.
    These active compounds may in particular be chosen from antibacterial agents, ion channel inhibitors, immunosuppressive agents and antiviral agents. For example, acyclovir can be cited as an antiviral agent.
    According to a particular aspect of the invention, the pharmaceutical or veterinary composition for its use in the prevention and / or treatment of an infection with the MERS-CoV coronavirus, comprises, in addition to apigenin and / or berberine, at least one other antiviral agent.
    According to another particular aspect of the invention, the pharmaceutical or veterinary composition for its use in the prevention and / or treatment of an infection with the MERS-CoV coronavirus, comprises, in addition to a combination of at least two compounds chosen from apigenin, berberine and monensin, at least one other antiviral agent.
    It is understood that this antiviral agent will be used at the doses necessary to exhibit an antiviral action, this dose being designated as being "effective", this dosage being able to be easily determined by a person skilled in the art.
    Within the meaning of the invention, an antiviral agent denotes a compound acting on a virus, by inhibiting and / or slowing down and / or preventing the associated viral infection.
    Antiviral agents are classified into different categories according to their mode of action. We can cite in particular:
    - nucleotide analogs, which interfere or stop the synthesis of DNA or RNA; as well as inhibitors of enzymes involved in the synthesis of DNA or RNA (helicase, replicase);
    - the compounds which inhibit the stages of maturation of the virus during its replication cycle;
    - compounds which interfere with the binding to the cell membrane, or the entry of viruses into host cells (fusion or entry inhibitors);
    - agents which prevent the virus from expressing itself within the host cell after it has entered, by blocking its disassembly within the cell;
    - agents that restrict the spread of viruses to other cells.
    Mention may in particular be made of antiviral agents well known to those skilled in the art, intended to fight against RNA viruses, such as protease inhibitors, helicase inhibitors, and inhibitors of cellular entry of the MERS- virus. CoV in target cells.
    Among the antiviral agents well known to those skilled in the art, there may be mentioned more precisely ribavirin, a nucleoside analog of guanosine with a broad antiviral spectrum; as well as interferon which works by inhibiting viral replication in host cells.
    According to a particular aspect of the invention, the pharmaceutical or veterinary composition is characterized in that the other antiviral agent is chosen from the following compounds: ribavirin, an interferon, or a combination of the two.
    For the purposes of the invention, the term "an interferon" or "interferon" means a compound belonging to the family of interferons, which are glycoproteins secreted by cells of the immune system.
    Interferons are a family of small protein molecules with a molecular weight of around 15,000 to 21,000 daltons. Three major classes of interferons have been identified: alpha, beta and gamma. These 3 main classes are not themselves homogeneous and can group together several different molecular species of interferon. More than 14 genetically different human alfa interferons have been identified.
    It is understood that in the pharmaceutical or veterinary composition according to the invention, the interferon used will be a recombinant polypeptide, synthesized in the laboratory.
    In particular, the interferon used will be the recombinant alfa-2b interferon, the efficacy of which on viral replication in vitro and in vivo has been demonstrated.
    Such antiviral agents are commercially available, and their conditions of use are described in reference works such as The Vidal Dictionary.
    Thus, the pharmaceutical composition for its use according to the invention may include one of the following combinations:
    - Apigenin, berberine and ribavirin;
    - Apigenin, berberine and interferon;
    - Apigenin, berberine, interferon and ribavirin;
    - Apigenin, monensine and ribavirin;
    - Apigenin, monensin and interferon;
    - Apigenin, monensin, interferon and ribavirin;
    - Berberine, monensine and ribavirin;
    - Berberine, monensine and interferon;
    - Berberine, monensine, interferon and ribavirin;
    - Apigenin, berberine, monensine and ribavirin;
    - Apigenin, berberine, monensine and interferon;
    - Apigenin, berberine, monensine, interferon and ribavirin.
    According to a particular aspect of the invention, the pharmaceutical composition for its use according to the invention will consist of a combination of active agents as mentioned above, and a suitable pharmaceutical vehicle.
    Method of administration of pharmaceutical or veterinary compositions
    The pharmaceutical and veterinary compositions for use according to the present invention are suitable for oral, sublingual, inhalation, subcutaneous, intramuscular, intravenous, transdermal, ocular or rectal administration.
    According to a particular implementation of the invention, the pharmaceutical or veterinary composition for its use according to the invention is characterized in that it is in a galenical form intended for administration by inhalation.
    Inhalation refers to absorption through the respiratory tract. It is in particular a method of absorption of compounds for therapeutic purposes, of certain substances in the form of gases, micro-droplets or powder in suspension.
    The administration of pharmaceutical or veterinary compositions by inhalation, that is to say by the nasal and / or buccal routes, is well known to those skilled in the art.
    There are two types of administration by inhalation:
    • administration by insufflation when the compositions are in the form of powders, and • administration by nebulization when the compositions are in the form of aerosols (suspensions) or in the form of solutions, for example aqueous solutions, under pressure. The use of a nebulizer or sprayer will then be recommended for administering the pharmaceutical or veterinary composition.
    The dosage form considered here is therefore chosen from: a powder, an aqueous suspension of droplets or a solution under pressure.
    Combination product
    The present invention also relates to a combination product comprising:
    a composition according to the invention, comprising at least one compound chosen from apigenin and berberine, optionally in the presence of monensin, and
    - at least one antiviral agent, for simultaneous, separate or sequential use to prevent and / or treat infection with the MERS-CoV coronavirus, in humans or animals.
    Such a combination product may be used in the prevention and / or treatment of an infection with the MERS-CoV coronavirus, in the context of simultaneous, separate or sequential use. Thus, the at least two active agents included in the combination product can be administered simultaneously, separately or sequentially.
    It is understood that all the combinations of two, three or four active compounds mentioned above can each be in the form of a combination product, that is to say that the two, three or four active compounds can be administered from simultaneously, separately or sequentially, to prevent and / or treat MERS-CoV coronavirus infection.
    The invention also relates to a therapeutic method for the prevention and / or treatment of a MERS-CoV coronavirus infection in humans, in which a patient is administered an effective amount of a compound chosen from apigenin and berberine, or a mixture of the two, optionally in combination with monensin.
    The invention also relates to a therapeutic method for the prevention and / or treatment of a MERS-CoV coronavirus infection in animals in which an animal is administered an effective amount of a compound chosen from apigenin. and berberine, optionally in combination with monensin.
    The invention also relates to the use of a compound chosen from apigenin and berberine, optionally in combination with monensin, for the preparation of a pharmaceutical composition intended for the prevention and / or treatment of MERS-CoV coronavirus infection.
    Pharmaceutical or veterinary compositions
    The present invention also relates to a pharmaceutical or veterinary composition, comprising, in an appropriate pharmaceutical vehicle, at least two compounds chosen from:
    (a) an antiviral agent; and (b) a compound selected from apigenin, berberine, and a combination of the two.
    In particular, the antiviral agent is intended to fight against an infection by the coronavirus MRES.
    The viral agent may in particular be chosen from:
    - nucleotide analogs, which interfere or stop the synthesis of DNA or RNA; as well as inhibitors of enzymes involved in the synthesis of DNA or RNA (helicase, replicase);
    - the compounds which inhibit the stages of maturation of the virus during its replication cycle;
    - compounds which interfere with the binding to the cell membrane, or the entry of viruses into host cells (fusion or entry inhibitors);
    - agents which prevent the virus from expressing itself in the host cell after its entry, by blocking its disassembly within the cell;
    - agents that restrict the spread of viruses to other cells.
    Mention may in particular be made of antiviral agents well known to those skilled in the art, intended to fight against RNA viruses, such as protease inhibitors, helicase inhibitors, and inhibitors of entry of the virus into cells. targets.
    Among the antiviral agents well known to those skilled in the art, there may be mentioned more precisely ribavirin, a nucleoside analog of guanosine with a broad antiviral spectrum; as well as interferon which works by inhibiting viral replication in host cells.
    According to a particular aspect of the invention, the composition contains, as an antiviral agent, an interferon, ribavirin, or a combination of the two.
    The pharmaceutical composition according to the invention may also include monensin.
    Thus, the pharmaceutical composition according to the invention may include one of the following combinations:
    - Apigenin and ribavirin;
    - Apigenin and interferon;
    - Apigenin, interferon and ribavirin;
    - Berberine and ribavirin;
    - Berberine and interferon;
    - Berberine, interferon and ribavirin;
    - Apigenin, berberine and ribavirin;
    - Apigenin, berberine and interferon;
    - Apigenin, berberine, interferon and ribavirin;
    - Apigenin, monensine and ribavirin;
    - Apigenin, monensin and interferon;
    - Apigenin, monensin, interferon and ribavirin;
    - Berberine, monensine and ribavirin;
    - Berberine, monensine and interferon;
    - Berberine, monensine, interferon and ribavirin;
    - Apigenin, berberine, monensine and ribavirin;
    - Apigenin, berberine, monensine and interferon;
    - Apigenin, berberine, monensine, interferon and ribavirin.
    According to a particular aspect of the invention, the pharmaceutical composition according to the invention will consist of a combination of active agents as mentioned above, and a suitable pharmaceutical vehicle.
    Such compositions may be used in any kind of therapeutic or prophylactic use, and will in particular be used in the treatment and / or prevention of viral infections.
    The compositions according to the invention may be of the pharmaceutical type, intended to be administered to a human being, or of the veterinary type, intended to be administered to non-human animals.
    As regards animals, the veterinary compositions according to the invention are in particular intended for mammals, in particular for production animals, and in particular for mammals of the camelid family, and very particularly for camels (genus Camelus).
    It should be noted, however, the fact that monensin has a high toxicity in horses (genus Equus) and that the veterinary compositions according to the invention comprising monensin are not intended for administration of mammals belonging to the genus Equus.XDq such compositions may in particular be used in the treatment and / or prevention of infections with coronaviruses, and very particularly with the MERS-CoV coronavirus.
    According to a particular implementation of the invention, such compositions may be in a dosage form intended for administration by inhalation.
    Berberine and monensine combination
    The present invention also relates to a pharmaceutical or veterinary composition, comprising in a suitable pharmaceutical vehicle, a combination of berberine and monensine.
    Said composition may be used in any kind of therapeutic or prophylactic use, and will in particular be used in the treatment and / or prevention of viral infections.
    Such a composition comprising a combination of berberine and monensin may in particular be used in the treatment and / or prevention of infections with coronaviruses, and very particularly with the coronavirus MERS-CoV.
    According to a particular implementation of the invention, this composition may be in a dosage form intended for administration by inhalation.
    EXAMPLES
    The examples presented below demonstrate that the compounds cited above unexpectedly exhibit significant antiviral activity against
    MERS-CoV, in vitro on two distinct models of mammalian cells, under moderate cytotoxicity conditions.
    Initially, the compounds were tested in vitro, at a concentration conventionally used in the literature, in the context of an infection of VERO-E6 cells by the strain of MERS-CoV France-UAE / 1612/2013, N ° accession Genbank KF745068.
    VERO-E6 cells are derived from monkey kidney epithelial cells and are susceptible to MERS-CoV infection. They constitute one of the cellular models of studies widely used in the literature.
    The infection parameters have been determined beforehand in order to obtain the best conditions for observing a possible antiviral effect.
    VERO-E6 cells were infected at an MOI (Multiplicity Of Infection) of 0.5 for a period of 24 hours at 37 ° C under 5% CO2, in the presence or absence of tested compounds.
    After 24 hours of incubation, the infectious titers (log10 DITC50 / ml or DITC50 / ml) were determined in the culture supernatants of infected cells.
    The infectious titers are indicated TCID50 / mL (50% Tissue Culture Infective Dose) in FiglA (log10 TCID50 / mL) and Fig IB (TCID50 / mL). They were obtained by infection technique by limiting dilution and calculation by the method of Reed and Muench.
    A cytotoxicity test and a quantification test for the coronavirus are carried out after 24 h of incubation. The cytotoxicity of the various compounds is determined on each test in a plate of non-infected cells by a viability test (MTS test, Promega). This test is based on the measurement of the metabolic activity of cells, which transforms a substrate (MTS tetrazolium) into a product (Formazan), soluble in the medium and whose absorbance measured at 490 nm proportionally reflects the number of living cells. . The ratio of the absorbance in each well to the average absorbance of the wells of the control cells (not treated with the compounds) is calculated and indicated in the diagrams as an index of cell viability (relative cell viability).
    The effect on viral production in vitro is measured by determination of the infectious titers (TCID50 / mL) carried out on VERO-E6 cells, the titers being calculated according to the Reed and Muench technique. The infectious titer ratio in each condition was expressed as a function of the infectious titer measured in the control condition (without treatment).
    The results are presented in Figures IA (infectious titers expressed in log10 TCID50 / mL) and IB (titers expressed in TCID50 / mL).
    The infectious titers measured under the experimental conditions in the presence of the test compounds are greatly reduced compared to the control condition, where the cells have been infected but not treated.
    In fact, monensin (6 μΜ), berberine (12.5 pM) and apigenin (15 pM) allow a reduction of 97.8%, 78.4% and 97.8% respectively of the infectious titers compared control (see Figure 1).
    From these results, a wider range of concentrations was tested for each of the three compounds on VeroE6 cells under the same experimental conditions, in order to determine the effective concentration range, and thus to determine an IC50 (half maximal Inhibitory Concentration) that is to say the dose necessary to obtain 50% inhibition of viral production (cf. FIG. 2).
    It was possible to determine an IC50 value for these three compounds:
    - 1.25 pM, for monensin
    - 3.8 pM for berberine and
    - 1.7 pM for apigenin.
    These IC50 values are relatively low compared to the usual concentrations known for these compounds in their applications outside the infectious field. These values are also very far from the cytotoxicity concentrations (CC50).
    Similar efficacy results were also obtained for these three compounds in another cell model of choice, that of the human respiratory epithelial cell line A549 (FIG. 3).
    BIBLIOGRAPHICAL REFERENCES
    PATENTS
    FR 2 953 410
    FRI 552284
    FR1653057
    WO 2016/013793 WO 2013/185126 US 2009/0149545
    WO 2015/157223
    NON PATENTS
    Emmie de Wit, Neeltje van Doremalen, Darryl Falzarano & Vincent J. Munster. SARS and MERS: recent insights into emerging coronaviruses. Nature Reviews Microbiology. 14,
    523-534 (2016).
    R. Dijkman, L. van der Hoek. Human coronaviruses 229E andNL63: close yet still so far. J Formos Med Assoc 108 (2009), pp. 270-279
    Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG Jr, Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ,
    Hensley LE, Frieman MB. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug; 58 (8): 4885-93.
    Jaffar A. Al-Tawfiq et al., Ribavirin and Interferon Therapy in Patients Infected with the Middle East Respiratory Syndrome Coronavirus: An Observational Study. International
    Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases 20 (March 2014): 42-46
    Josset L, Menachery VD, Gralinski LE, Agnihothram S, Sova P, Carter VS, Yount BL, Graham RL, Baric RS, Katze MG. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus.MBto. 2013 Apr 30; 4
    Adedeji AO, Sarafianos SG. Antiviral drugs specifies for coronaviruses in preclinical development.Curr Opin Virol. 2014 Oct; 8: 45-53.
    Kilianski A, Baker SC. Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors. Antiviral Res. 2014 Jan; 101: 105-12.
    Shibata C, Ohno M, Otsuka M, Kishikawa T, Goto K, Muroyama R, Kato N, Yoshikawa T, Takata A, Koike K. The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology. 2014 Aug; 462-463: 42-8.
    Lv X, Qiu M, Chen D, Zheng N, Jin Y, Wu Z. Apigenin inhibits enterovirus 71 replication through viral suppressing IRES activity and modulating cellular JNK pathway. Antiviral Res. 2014 Jun 24; 109C: 30-41.)
    Song S, Qiu M, Chu Y, Chen D, Wang X, Su A, Wu Z. Berberine down-regulates cellular JNK and NF-κΒ activation and this may resuit in an inhibition of HSV replication.
    Antimicrob Agents Chemother. 2014 Jun 9.
    Wu Y, Li JQ, Kim YJ, Wu J, Wang Q, Hao Y. In vivo and in vitro antiviral effects of berberine on influenza virus. Chin J Integr Med.
    2011 Jun; 17 (6): 444-52.
    权利要求:
    Claims (10)
    [1" id="c-fr-0001]
    1. Pharmaceutical or veterinary composition for its use in the prevention and / or treatment of an infection with the coronavirus MERS-CoV (Middle-East Respiratory Syndrome), characterized in that it comprises, in an appropriate pharmaceutical vehicle, minus one compound chosen from Apigenin and Berberine.
    [2" id="c-fr-0002]
    2. Pharmaceutical or veterinary composition for its use according to claim 1, characterized in that it comprises a combination of at least two of the following compounds: Apigenin, Berberine and Monensine.
    [3" id="c-fr-0003]
    3. Pharmaceutical or veterinary composition for use according to one of claims 1 to 2, characterized in that it further comprises at least one other antiviral agent.
    [4" id="c-fr-0004]
    4. Pharmaceutical or veterinary composition for its use according to claim 3, characterized in that the other antiviral agent is chosen from the following compounds: a protease inhibitor, a helicase inhibitor, and an inhibitor of cell entry of the MERS-CoV virus.
    [5" id="c-fr-0005]
    5. Pharmaceutical or veterinary composition for its use according to claim 3 or 4, characterized in that the other antiviral agent is chosen from the following compounds: ribavirin, an interferon, or a combination of the two.
    [6" id="c-fr-0006]
    6. Pharmaceutical or veterinary composition for its use according to one of claims 1 to 5, characterized in that it is in a galenical form intended for administration by inhalation.
    [7" id="c-fr-0007]
    7. Pharmaceutical or veterinary composition, comprising, in an appropriate pharmaceutical vehicle, at least two compounds chosen from:
    (a) an antiviral agent; and (b) a compound selected from apigenin, berberine, and a combination of the two.
    [8" id="c-fr-0008]
    8. Pharmaceutical or veterinary composition according to claim 7, characterized in that the antiviral agent is an interferon, ribavirin, or a combination of the two.
    [9" id="c-fr-0009]
    9. Pharmaceutical or veterinary composition, comprising in a suitable pharmaceutical carrier, a combination of berberine and monensine.
    [10" id="c-fr-0010]
    10. Pharmaceutical or veterinary composition according to one of claims 7 to 9, characterized in that it is in a galenical form intended for administration by inhalation.
    A B
    TTïirc inifectieu x. {loglû TCtDSO / mlLJ
    类似技术:
    公开号 | 公开日 | 专利标题
    EP3528835B1|2021-03-03|Antiviral compositions for the treatment of infections linked to coronaviruses
    Zhang et al.2016|Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer
    Pooladanda et al.2020|The current understanding and potential therapeutic options to combat COVID-19
    Zhang et al.2013|Identification of plumbagin and sanguinarine as effective chemotherapeutic agents for treatment of schistosomiasis
    Ripari et al.2021|Propolis antiviral and immunomodulatory activity: a review and perspectives for COVID-19 treatment
    KR20180125552A|2018-11-23|Thiazolide compounds for treating viral infections
    CA2979784A1|2016-09-22|Novel antiviral compositions for treating the flu
    CA2746437C|2014-07-08|Composition for the prevention and treatment of viral infections
    Teng et al.2021|Plant-derived exosomal microRNAs inhibit lung inflammation induced by exosomes SARS-CoV-2 Nsp12
    Wilson et al.2014|Diseases of the central nervous system caused by lymphocytic choriomeningitis virus and other arenaviruses
    BR112015026243B1|2020-09-29|USES OF RETINOIC ACID ANALOGS FOR TREATMENT AND PROVISION OF VIRAL INHIBITION OF VIRAL INFECTIONS
    US20090281065A1|2009-11-12|Use of Lysophospholipids to Treat Inflammation
    FR3081325A1|2019-11-29|DILTIAZEM FOR USE IN THE TREATMENT OF MICROBIAL INFECTIONS
    WO2017174593A1|2017-10-12|Novel antiviral compositions for the treatment of influenza
    LU85854A1|1985-12-16|METHOD OF MEDICAL TREATMENT OF VIRAL DISEASES USING 1-BETA-D-RIBOFURANNOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE
    TWI359669B|2012-03-11|
    WO2021205083A2|2021-10-14|Composition for the prevention or treatment of covid-19
    FR3108033A1|2021-09-17|ANTIVIRAL COMPOUNDS AND THEIR COMBINATIONS FOR TREATING VIRAL INFECTION WITH SARS-CoV-2
    JP7005611B2|2022-01-27|Antiviral composition for the treatment of infectious diseases associated with coronavirus
    WO2021244481A1|2021-12-09|Compositions and methods for treating a sars-cov-2 infection
    BR102019014081A2|2021-01-19|immunomodulatory compounds and / or their pharmaceutically acceptable salts, pharmaceutical composition comprising immunomodulatory compounds and use of immunomodulatory compounds in the preparation of a pharmaceutical composition for treating viral diseases
    FR3106055A1|2021-07-16|COMBINATION OF DILTIAZEM AND OTHER ANTIVIRAL AGENTS
    FR2923160A1|2009-05-08|Use of a compound for preparing pharmaceutical composition e.g. to prevent and/or treat viral infection, inhibit viral replication, prevent and/or inhibit synthesis of viral proteins and prevent and/or inhibit the increased cell death
    KR101673432B1|2016-11-07|Anti-viral Composition Containing the Extract of Gleditsia spina
    FR3109724A1|2021-11-05|Benzoporphyrin derivative and its use as an anti-viral
    同族专利:
    公开号 | 公开日
    KR102265798B1|2021-06-15|
    EP3528835B1|2021-03-03|
    RU2019114665A|2020-11-23|
    IL266119A|2021-01-31|
    KR20190071765A|2019-06-24|
    BR112019007931A2|2019-07-02|
    RU2753534C2|2021-08-17|
    US20190307722A1|2019-10-10|
    ZA201903161B|2020-09-30|
    JP2019535667A|2019-12-12|
    WO2018073549A1|2018-04-26|
    RU2019114665A3|2021-01-20|
    EP3528835A1|2019-08-28|
    IL266119D0|2019-06-30|
    TN2019000126A1|2020-10-05|
    CA3041165A1|2018-04-26|
    FR3057773B1|2020-06-19|
    TW201817430A|2018-05-16|
    CN110035767B|2021-08-31|
    CN110035767A|2019-07-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    CN1089851A|1993-01-20|1994-07-27|曹青春|Control cold spray and preparation method thereof|
    WO2004037237A1|2002-10-24|2004-05-06|Immupharm A/S|Pharmaceutical compositions comprising flavonoids and menthol|
    US20110218241A1|2010-03-06|2011-09-08|Cacao Bio-Technologies, Llc|Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts|
    WO2015157223A1|2014-04-07|2015-10-15|University Of Maryland, Baltimore|Methods of treating coronavirus infection|CN108721271A|2018-05-04|2018-11-02|中国疾病预防控制中心病毒病预防控制所|Application of the Monensin in preparing wide spectrum anti-coronavirus drug|TWI343810B|2003-05-28|2011-06-21|Nat Health Research Institutes|A pharmaceutical composition for inhibiting coronavirus|
    CN101108200A|2006-04-21|2008-01-23|朱耕新|Composition of starwort sulphonic acid or vitriolic acid polyoses ester total phenolic glycoside and method of preparing the same and antiviral application|
    CN101829113B|2009-07-14|2012-12-12|武汉大学|Application of berberine in medicine for treating or preventing influenza virus|
    FR2953410B1|2009-12-09|2012-02-24|Univ Claude Bernard Lyon|PHARMACEUTICAL OR VETERINARY ANTIVIRAL COMPOSITIONS|
    WO2013185126A2|2012-06-08|2013-12-12|Lankenau Institute For Medical Research|Compositions and methods for tight junction modulation|
    WO2016013793A1|2014-07-24|2016-01-28|고려대학교 산학협력단|Use of robinia pseudoacacia extracts, acacetin and apigenin for use in improvement and treatment of gamma herpes virus infection|
    FR3033701B1|2015-03-19|2021-01-15|Univ Claude Bernard Lyon|NEW ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFLUENZA|
    FR3049861A1|2016-04-07|2017-10-13|Univ Claude Bernard Lyon|NOVEL ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFLUENZA|WO2021183456A1|2020-03-08|2021-09-16|Humanigen, Inc.|Methods for treating coronavirus infection and resulting inflammation-induced lung injury|
    FR3108033A1|2020-03-10|2021-09-17|Universite Claude Bernard Lyon 1|ANTIVIRAL COMPOUNDS AND THEIR COMBINATIONS FOR TREATING VIRAL INFECTION WITH SARS-CoV-2|
    WO2021207176A1|2020-04-06|2021-10-14|Humanetics Corporation|Genistein treatment of inflammatory pulmonary injury|
    WO2021212183A1|2020-04-24|2021-10-28|Centre For Digestive Diseases Pty Limited|Products of manufacture and methods for treating, ameliorating or preventing microbial infections|
    DE102020002742A1|2020-05-07|2021-11-11|Mathias Ebert|Florviamin|
    CN112220808A|2020-11-18|2021-01-15|上海中医药大学|Ephedra extract and active component and application thereof|
    法律状态:
    2017-10-31| PLFP| Fee payment|Year of fee payment: 2 |
    2018-04-27| PLSC| Publication of the preliminary search report|Effective date: 20180427 |
    2018-10-10| PLFP| Fee payment|Year of fee payment: 3 |
    2019-10-08| PLFP| Fee payment|Year of fee payment: 4 |
    2020-10-30| PLFP| Fee payment|Year of fee payment: 5 |
    2021-10-26| PLFP| Fee payment|Year of fee payment: 6 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1660223|2016-10-21|
    FR1660223A|FR3057773B1|2016-10-21|2016-10-21|NOVEL ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS-RELATED INFECTIONS|FR1660223A| FR3057773B1|2016-10-21|2016-10-21|NOVEL ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS-RELATED INFECTIONS|
    CN201780064143.0A| CN110035767B|2016-10-21|2017-10-20|Antiviral composition for treating infections associated with coronaviruses|
    EP17797395.5A| EP3528835B1|2016-10-21|2017-10-20|Antiviral compositions for the treatment of infections linked to coronaviruses|
    RU2019114665A| RU2753534C2|2016-10-21|2017-10-20|Antiviral compositions for the treatment of coronavirus-related infections|
    US16/340,346| US20190307722A1|2016-10-21|2017-10-20|Antiviral compositions for the treatment of infections linked to coronaviruses|
    PCT/FR2017/052889| WO2018073549A1|2016-10-21|2017-10-20|Antiviral compositions for the treatment of infections linked to coronaviruses|
    TNP/2019/000126A| TN2019000126A1|2016-10-21|2017-10-20|NEW ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS-RELATED INFECTIONS.|
    JP2019521029A| JP7005611B2|2016-10-21|2017-10-20|Antiviral composition for the treatment of infectious diseases associated with coronavirus|
    CA3041165A| CA3041165A1|2016-10-21|2017-10-20|Antiviral compositions for the treatment of infections linked to coronaviruses|
    KR1020197014234A| KR102265798B1|2016-10-21|2017-10-20|Antiviral composition for treatment of infection associated with coronavirus|
    BR112019007931A| BR112019007931A2|2016-10-21|2017-10-20|antiviral compositions for the treatment of coronavirus-related infections|
    TW106136358A| TW201817430A|2016-10-21|2017-10-23|New antiviral compositions for the treatment of coronavirus-related infections|
    IL266119A| IL266119A|2016-10-21|2019-04-18|Antiviral compositions for the treatment of infections linked to coronaviruses|
    ZA2019/03161A| ZA201903161B|2016-10-21|2019-05-20|Antiviral compositions for the treatment of infections linked to coronaviruses|
    [返回顶部]